Elevated Lipoprotein(a) in Hospital Staff (LPACO)

March 16, 2026 updated by: Loh Wann Jia, Changi General Hospital

Investigating The Prevalence and Clinical Significance of Elevated Lipoprotein(a) Blood Levels in Hospital Staff

The objective of this study is to investigate the prevalence of elevated Lp(a) in the working general population.

Study Overview

Status

Active, not recruiting

Conditions

Detailed Description

The objective of this study is to investigate the prevalence of elevated lipoprotein(a) concentrations and distribution of lipoprotein(a) in a working general population. This is a prospective study investigating the association of lipoprotein(a) with cardiovascular markers and outcomes.

Study Type

Observational

Enrollment (Estimated)

2800

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Singapore
    • Singapore
      • Singapore, Singapore, Singapore, 529889
        • Clinical Trials & Research Unit

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Working general population

Description

Inclusion Criteria:

  1. Any healthcare workers working in healthcare settings (regardless of PHI and/or private setting) aged 21 and above OR family member such as father, mother, siblings, grandparents, spouse and children aged 12 and above of recruited staff with high Lpa ≥120nmol/l
  2. Study team members can also be recruited because we are trying to find the prevalence of elevated Lp(a)

Exclusion Criteria:

  1. Inability to provide informed consent.
  2. Pregnant women.
  3. Prisoner

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Working General Population
Consenting hospital staff are recruited to this study. Blood test and questionnaires are taken at baseline. Prospective follow-up of cardiovascular events are undertaken.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Distribution and prevalence of elevated Lipoprotein(a)
Time Frame: 3 years
Investigate the distribution lipoprotein(a) and prevalence of elevated lipoprotein(a) concentrations in various ethnicities.
3 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Correlation of lipoprotein(a) with cardiovascular outcomes
Time Frame: 10 years
Observational study to assess the correlation of degree of elevation of lipoprotein(a) with cardiovascular outcomes prospectively.
10 years
Genetic variants of lipoprotein(a) and cardiovascular outcomes atherosclerotic events
Time Frame: 10 years
Assess the association of genetic variants of lipoprotein(a) with the measured lipoprotein(a) concentrations in various ethnicities, and prospectively assess the association of these genetic variants with cardiovascular outcomes
10 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Changi General Hospital

Investigators

  • Principal Investigator: Loh Wann Jia, Singhealth Foundation

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2024

Primary Completion (Estimated)

December 1, 2035

Study Completion (Estimated)

December 31, 2036

Study Registration Dates

First Submitted

March 5, 2024

First Submitted That Met QC Criteria

March 5, 2024

First Posted (Actual)

March 12, 2024

Study Record Updates

Last Update Posted (Actual)

March 18, 2026

Last Update Submitted That Met QC Criteria

March 16, 2026

Last Verified

August 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CIRB2023/2651

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Diseases

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe